Members were emailed their invoices two weeks ago.
If you are not a member click the Join TTS button below!

Latest Video Content Posted

Videos from the Congress are now available to TTS Members.

SPLIT 2020 Meeting videos are now available to TTS & SPLIT Members.

Beta Cells Summit videos are now available to TTS & IPITA Members.


Click to view (TTS Members only)

Nov 19 - Tips and Tricks for Virtual Care in Pediatric Transplant - IPTA Allied Health and Nursing Professionals Webinar - Ashley Graham, Julie Guillen, Lisa Remaley, Robin Deliva, Anna Galloway, Rosa Reed-Berendt

Click to view (IPTA or TTS Members only)

TTS-ILTS Paired Transplant Centers Program
Application Deadline - January 1, 2021

The TTS-ILTS Paired Transplant Centers Program is a collaboration between The Transplantation Society (TTS) and the International Liver Transplantation Society (ILTS) supporting new liver transplant programs in emerging economies.

TTS and TTS Sections News

WIT Virtual Networking Event – Today!

Call for TTS Committee Members


Every two years, TTS reviews the membership in its Committees to ensure that they are representative of the overall TTS membership.

The role of the Committees within TTS are extremely important to ensure the ongoing development of our Society and make certain that it continues to meet the needs to our membership. As such, it is important that we have a good representation on each committee to address the varied needs of our membership, whether from a geographic, gender or role perspective.

In reviewed the composition of our Committees, we find that the vast majority have good, balanced representation. However, some Committees would benefit from increased diversity, particularly from a geographic standpoint. As such, we are seeking self-nominations to participate in the following Committees: Heart and Lung Committee, Membership Committee and Young Members Committee

Though we have identified needs for additional geographic representation based on the above criteria, we welcome any self-nominations. The Committee Chairs will review the self-nominations to ensure a complete and balanced Committee.

The only expectation of nominees is that they actively participate in committee activities and lead the work of their committee within their respective regions.


ISODP 2023 Call for Hosting

Letter of Intent Deadline - December 15, 2020

Every two years, the ISODP Congress brings together clinicians and scientists from all parts of the world in the fields of organ procurement and donation

Click here to download the Call for Hosting

COVID-19: Organ Donation and Transplant Town Hall #4

Tomorrow! December 3, 2020, 3:00-4:30 PM EDT
Registration will open at 10:00 AM ET on Thursday, November 19


A number of transplant organizations from around the world continue their partnership to create a fourth educational webinar for the organ donation and transplantation communities. Our goal is to share experiences to date and respond to your questions about the impact of COVID-19 on organ donation and transplantation.

Talks will include:

  • What happened to transplantation during the COVID-19 Pandemic?
    • U.S. Experience (David Klassen, MD, UNOS)
    • European Experience (John Forsythe, National Blood Service, Transplant, UK)
  • What happened to the waitlist and outcomes during the pandemic?
    • U.S. Experience (Lloyd Ratner, MD, ASTS, AST)
    • European Experience (Patrizia Burra, MD PhD, ESOT)
  • Impact of COVID-19 on the Workforce: The Challenges of Burnout
  • The Current and Future State of Transplantation during the Pandemic
    • Strategies for doing COVID care and non COVID care simultaneously (Atul Humar, MD CST, AST)
    • Testing strategies and time-based clearance for those with history of COVID, including those awaiting transplant and in need of treatment for other medical issues, including rejection
    • Therapeutics for SARS-CoV-2 infection in transplant candidates and recipients (Michael Ison, MD, AST, TTS)
    • What is the future of vaccination, including for transplant candidates and recipients?

Special Thanks To:


WMA Statement on Measures for the Prevention and Fight against Transplant-Related Crimes

TTS fully endorses the WMA Statement on Measures for the Prevention and Fight Against Transplant-Related Crimes


Dr. Jeremy R. Chapman, Editor-in-Chief, Transplantation

COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?

Avery RK
Transplantation: October 29, 2020 - Volume Online First

This useful summary of the therapeutic approaches to COVID-19 in transplant populations separates the early weeks and months when data were lacking in both the general and organ transplant populations from the later era as data became available. The first era involved use of drugs such as hydroxychloroquine with or without azithromycin, lopinavir-ritonavir, and tocilizumab with little or no effect. With the publication of larger trials, remdesivir, dexamethasone, and convalescent plasma have been advised. There is now a large number of clinical trials of investigational and repurposed agents with antiviral or immunomodulatory effects. This organ transplant focussed overview will help those working to contain the impact of the current waves of COVID-19 globally.




Selected Publications by TTS Education Committee. This week's selection made by Enver Akalin, Gabriel Gondolesi and Millie Samaniego

Prevention of severe COVID-19 in the elderly by early high titer plasma

Romina Libster et al.
medRxiv. preprint doi:;
This version posted November 21, 2020.

Therapies to interrupt progression of early COVID-19 remain elusive. Among them, convalescent plasma in hospitalized patients was unsuccessful, perhaps because antibody should be administered earlier. A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV2 in elderly subjects within 72 hours of mild COVID-19 symptoms. The primary endpoint was severe respiratory disease defined as a respiratory rate ≥30 and/or an O2 sat<93% in room air. 160 patients underwent randomization. In the intention-to-treat analysis (ITT), 13/80(16.2%) patients receiving plasma vs. 25/80(31.2%) receiving placebo experienced severe respiratory disease [RR(95%CI)= 0.52(0.29,0.94); p=0.026)] with an RRR=48%. High- and low-titer donor analyses, based on a median IgG titer=1:3,200, evidenced a dose-dependent response with an RRR=73.3% for recipients of high-titer plasma (p=0.016) and a number needed to treat (NNT)=4.4. All secondary endpoints exhibited trends towards protection. No solicited adverse events were observed. Early administration of high-titer convalescent plasma against SARSCoV2 to mildly ill infected seniors reduced COVID-19 progression.

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Kristina L. Bajema et al.
JAMA Intern Med. doi:10.1001/jamainternmed.2020.7976
Published online November 24, 2020.

In this repeated, cross-sectional study of 177 919 residual clinical specimens, the estimated percentage of persons in a jurisdiction with detectable SARS-CoV-2 antibodies ranged from fewer than 1% to 23%. Over 4 sampling periods in 42 of 49 jurisdictions with calculated estimates, fewer than 10% of people had detectable SARS-CoV-2 antibodies.

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Ventura A. Simonovich et al.
NEJM, November 24, 2020. DOI: 10.1056/NEJMoa2031304

In this study, A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200]. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83 (95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups.


The Transplantation Society (TTS) and our journal Transplantation have developed online resources to keep you informed on the Coronavirus (COVID-19) outbreak.

We are also requesting contributions and news from the transplant community to be sent to for inclusion on our resources page.


In this dashboard, you will find links to TTS and other global and regional resources, as well as interactive maps, publications and webinars. We encourage you to explore this dashboard and share with your colleagues.

Website -


Editors and contributors to Transplantation have shared their thoughts on how they are dealing with the current crisis. While we understand that the information of today may be quite different tomorrow in this fast-moving pandemic, this report will open our forum of an international exchange on COVID for the transplant community.

Website -

Please send your own contributions and news to for inclusion on our resources page.


Hypothermic oxygenated perfusion vs normothermic regional perfusion in liver transplantation from controlled donation after circulatory death: First international comparative study

Nov. 24 - Since liver transplantation following cDCD is correlated with higher rates of graft loss, researchers sought to compare HOPE and NRP in liver transplantation from cDCD. They evaluated outcomes after cDCD liver transplantation in 1 Swiss (HOPE) and 6 French (NRP) centers in this retrospective comparative cohort study.


Life-Saving App Expedites Organ Transplant Medical Flights

Nov. 24 - When it comes to organ transplants, there is no time to lose trying to find a medical flight. In order to simplify and expedite the process, what is needed is a centralized network hub that can work out all the details, explains Sim Shain, CEO and Founder of ParaFlight EMS and Aviation, and


Aussie research on bioprinting mini kidney raises hope for lab-grown transplantation

Nov. 24 - By using a technology involving a process similar to 3D printing, Australian researchers have produced a large number of man-made tiny kidneys with stable quality, taking one step closer to the reality of bio-printed kidney for human organ transplantation.


Signaling switch in pancreatic beta-cells determines anti-diabetic drug effectiveness

Nov. 25 - An international research group has clarified the action mechanism of incretin-based drugs in the treatment of diabetes. Incretin-based drugs are used worldwide in the treatment of diabetes and in Japan they are currently prescribed to 70% of diabetic patients. However, the mechanism by which incretin-based drugs improve blood glucose levels has been poorly understood.



Asian Transplantation Week (ATW) 2020

December 3-5, 2020 • Virtual Congress

International Symposium on Benign and Malignant Tumors in Liver With or Without Cirrhosis

24-25 June, 2021 • Kızılcahamam-Turkey



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6